Skip to content

ENDOCUR - Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults

Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03329781
Acronym
ENDOCUR
Enrollment
16
Registered
2017-11-06
Start date
2015-02-28
Completion date
2018-01-31
Last updated
2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Keywords

Endotoxaemia, Curcumin.

Brief summary

Chronic diseases such as diabetes, cardiovascular diseases and cancer are a major burden on the Scottish population. Obesity and inflammation have strong links to these diseases. One of the mechanisms explaining the relationship between low-grade inflammation and excess weight is endotoxaemia. We wish to study this phenomenon, when small components coming from our gut bacteria can pass into the bloodstream, raising the body's defences. Diet can modulate endotoxaemia. In this study, we propose to use curcumin, in a capsule form, to modulate endotoxaemia. Curcumin comes from turmeric, which is widely used as a spice. In this study, we want to test the effect of consuming curcumin extract to the composition of the gut microbiota, post-meal endotoxaemia, and inflammatory markers in blood.

Interventions

DIETARY_SUPPLEMENTBCM-95

Consuming 1 capsule of BCM-95 per day.

DIETARY_SUPPLEMENTPlacebo

Consuming 1 placebo capsule per day

Sponsors

University of Glasgow
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

\- BMI \> 25 kg/m2.

Exclusion criteria

* having chronic inflammatory or autoimmune disease, gastrointestinal complaints or known biliary obstruction (past and present) * use of anti-inflammatory drugs 2 weeks before the start of the study * use of antibiotics during the 12 weeks preceding the trial * pregnancy * lactation

Design outcomes

Primary

MeasureTime frame
Level of endotoxin in plasma.21 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026